- STAT+: Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drugAhead of a hearing, the FDA raised questions about the benefits of a Duchenne treatment from Capricor Therapeutics, another twist for the rare disease drug.STAT · 16m ago↗ source
- Sarepta turns to Michael Severino as CEO, looking to move past recent turmoilSarepta Therapeutics has found its new CEO as it seeks to recover from a calamitous past year. Michael Severino will replace the company’s longtime leader Doug Ingram on Tuesday. Severino joins f…Endpoints · 54m ago↗ source
- A trend that isn’t fading, ultra-processed baby foodsAn FDA advisory panel serves some peptide wins, a measles record, and more health news from Morning RoundsSTAT · 1h ago